Journals / Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi / 2013 / Cilt: 59 - Sayı: 4

Osteoporosis treatment at present and in the future

Günümüzde ve gelecekte osteoporoz tedavisi

Pages
330–337
Publication Date
2022-11-03
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Besides medical treatment, correspondingly with the progress in computer technology, physical therapy and rehabilitation modalities will continue to play an important role in improving the quality of life of patients with osteoporosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Osteoporosis is a growing health problem with the aging of the World’spopulation.
📊
Key Findings & Data:The aim of the new treatment options, modalities, and strategies is to increase bone formation and to inhibit excessive resorption.
💡
Conclusion & Impact:Besides medical treatment, correspondingly with the progress in computer technology, physical therapy and rehabilitation modalities will continue to play an important role in improving the quality of life of patients with osteoporosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Osteoporosis is a growing health problem with the aging of the World’spopulation. The primary goal of osteoporosis treatment at present and in the future is to prevent fractures. A wide range of medications including both antiresorptive and anabolic agents are available for the prevention of fractures. The diagnosis and treatment of osteoporosis are progressing rapidly in parallel with the research studies in the field of nanotechnology and pharmacogenetics. The aim of the new treatment options, modalities, and strategies is to increase bone formation and to inhibit excessive resorption. Besides medical treatment, correspondingly with the progress in computer technology, physical therapy and rehabilitation modalities will continue to play an important role in improving the quality of life of patients with osteoporosis.

Özet

Osteoporoz, ülkelerin nüfuslarının yaşlanması ile giderek artan önemli bir sağlık problemidir. Osteoporozun tedavisinde, günümüzde ve gelecekteprimer amaç kırıkların önlenmesidir. Osteoporotik kırıkların önlenmesindeantirezorbtif ve anabolik ajanlar olmak üzere geniş bir aralıkta ilaç grubu vardır. Nanoteknolojik ve farmakogenetik alandaki çalışmalarla osteoporozda tanı ve tedavi hızla gelişmektedir. Yeni tedavi seçenekleri, modelleri ve stratejilerininamacı, kemik formasyonunu arttırmak ve aşırı kemik rezorbsiyonunu önlenmektir. Medikal tedavinin yanısıra kullanılan fizik tedavi ve rehabilitasyon yöntemleri bilgisayar teknolojisindeki gelişmelerle orantılı olarak hastaların yaşam kalitesini artırmada önemli bir rol oynamaya devam edecektir.

🔖

Cite This Article

SİNDEL, D. (2022). Osteoporosis treatment at present and in the future. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi, Cilt: 59 - Sayı: 4, 330–337. https://ajindex.com/articles/628873

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Warriner AH, Saag KG. Osteoporosis diagnosis and medical treatment. Orthop Clin North Am 2013;44:125-35
  2. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011;377:1276-87
  3. Lippuner K. The future of osteoporosis treatment - a research update. Swiss Med Wkly 2012;142:13624
  4. Deal CL, Abelson AG, Carey JJ. Management of osteoporosis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, weisman MH, editors. Rheumatology. 4th ed. Philadelphia: Mosby Elsevier; 2008. p. 1955-68
  5. Sindel D, Ketenci A. Osteoporozda klinik bulgular ve görüntüleme. İçinde: Ataman Ş, Peyman Y, editörler. Romatoloji Kitabı. Ankara: MN Medikal&Nobel Tıp Kitabevi; 2012. s. 1125-40
  6. Sindel D. Tanı ve ayırıcı tanı. İçinde: Gökçe-Kutsal Y, editör. Osteoporoz Cep Kitabı, Ankara: Güneş Kitabevi; 2005. s. 69-87
  7. Sindel D. Sekonder osteoporoz. İçinde: Gökçe-Kutsal Y, editör. Modern Tıp Seminerleri: 19, Osteoporoz. Ankara: Güneş Kitabevi; 2001. s. 66-81
  8. National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2013
  9. Lentle B, Cheung AM, Hanley DA, Leslie WD, Lyons D, Papaioannou A, et al. Osteoporosis Canada 2010 guidelines for the assessment of fracture risk. Can Assoc Radiol J 2011;62:243-50
  10. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013;24:23-57
  11. Cauley JA, El-Hajj Fuleihan G, Arabi A, Fujiwara S, Ragi-Eis S, Calderon A, et al. Official Positions for FRAX® clinical regarding international differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom 2011;14:240-62
  12. FRAX WHO Fracture Risk Assessment Tool. http://www.shef.ac.uk/ FRAX/ 13. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP Feldman S, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010;182:1864-73
  13. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporo